Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma

Journal of Pathology

Volumn 186, Issue 1, 1998, Pages 51-58

  Väisänen, Anne ^a   Kallioinen, Matti ^a   Taskinen, Pentti J ^a   Turpeenniemi Hujanen, Taina ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

72 kD type IV collagenase; Gelatinases; Melanoma; Metastasis; MMP 2

Indexed keywords

GELATINASE A;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GELATINASES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 2; MELANOMA; METALLOENDOPEPTIDASES; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES; SEX FACTORS; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0031678829     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199809)186:1<51::AID-PATH131>3.0.CO;2-P     Document Type: Article

References (36)

1. Clark WH Jr, From L, Bernhardino EA, Mihm MC. The histogenesis and biological behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29: 705-726.
2. Breslow A. Thickness, cross-sectional areas and depth of invasion in prognosis of cutaneous melanoma. Ann Surg 1970: 172: 902-908.
3. Lee JAH. Etiology, epidemiology, and prognosis of melanoma and skin neoplasms. Curr Opin Oncol 1990; 2: 388-393.
4. Somma S, Glassman D. Malignant melanoma. Dermatol Nurs 1991; 3: 93-99.
5. Koh HK. Cutaneous melanoma. N Engl J Meet 1991; 325: 171-182.
6. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995; 75: 2484-2491.
7. Barth A, Morton D. The role of adjuvant therapy in melanoma management. Cancer 1995; 75: 726-734.
8. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Trial Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
9. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CH, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-68.
10. Liotta LA, Steeg P, Stetler-Stevenson VV. Cancer metastasis and angiogenesis. An imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
11. De Vries TJ, Ouax PHA, Denijn M, et al. Plasminogen activators, their inhibitors and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994; 144: 70-81.
12. De Wit ?, van Muijen GN, de Waal RM, Ruiter DJ. Pathology of malignant melanoma, including new markers and techniques. Curr Opin Oncol 1996; 8: 143-151.
13. De Vries TJ, Mooy CM, Van Balken MR, et al. Components of the plasminogen activation system in uveal melanoma - a clinico-pathological study. J Pathol 1995; 175: 59-67.
14. Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant SS, Liotta LA. Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids which differ in metastatic potential. J Natl Cancer Inst 1985; 75: 99-103.
15. Terranova VP, Hujanen ES, Loeb DM, Martin GR, Thornburg L, Glushko V. Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells. Proc Natl Acad Sci (Wash) 1986; 83: 465-469.
16. Höyhtyä M, Hujanen R, Turpeenniemi-Hujanen T, Thorgeirsson U, Liotta LA, Tryggvason K. Modulation of type IV collagenase activity and invasive behavior of metastatic human melanoma (A 2058) cells in vitro by monoclonal antibodies to type IV collagenase. Int J Cancer 1990; 46: 282-286.
17. Hujanen ES. Turpeenniemi-Hujanen T. Recombinant interferon alpha and gamma modulate the invasive potential of human melanoma in vitro. Int J Canter 1991; 47: 576-581.
18. Hendrix MJ, Wood WR, Seftor EA, et al. Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res 1990; 50: 4121-4130.
19. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996; 180: 283-289.
20. Ketcham AS, Moffat FL, Balch CM. Classification and staging. In: Balch CM, Houghton AA, Milton GW, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. Philadelphia: J. B. Lippincott, 1992; 213-220.
21. Turpeenniemi-Hujanen T, Rönnberg L, Kauppila A, Puistola U. Laminin in the human embryo implantation: analogy to the invasion by malignant cells. Fertil Steril 1992; 58: 105-113.
22. Höyhtyä M, Turpeenniemi-Hujanen T, Stetler-Stevenson W, Krutzsch H, Tryggvason K, Liotta LA. Monoclonal antibodies to type IV collagenase recognize a protein with limited sequence homology to interstitial collagenase and stromelysin. FEBS Lett 1988; 233: 109-113.
23. Lever WF, Schaumburg-Lever G. In: Histopathology of the Skin. 7th edn. Philadelphia: J, B. Lippincott, 1990; 756-805.
24. Hsu SM, Raine L, Fanger H. The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 557-580.
25. Cox DR. Regression model and life tables (with discussion). J R Stat Soc Br 1972; 34: 187-220.
26. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Kia Ang K. Cutaneous melanoma. In: DeVita VT Jr. Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology. 5th edn. Philadelphia: J. B. Lippincott, 1997; 1947-1994.
27. Tryggvason K, Höyhtyä M, Pyke C. Type IV collagenase in invasive tumors. Breast Cancer Res Treat 1993; 24: 209-218.
28. Höyhtyä M, Fridman R, Komarck D, et al. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies. Int J Cancer 1994; 54: 500-505.
29. Poulsom R, Pignatelli M, Stetler-Stevenson WG, et al. Stromal expression of 72 kD type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389-396.
30. Pyke C, Ralfkiaer E, Tryggvason K, Dano K. Messenger RNA for two type IV collagenases is located in nonmalignant stromal cells in human colon cancer. Am J Pathol 1993; 142: 359-365.
31. Karjalainen S, Hakulinen T. Survival and prognostic factors of patients with skin melanoma. A regression-model analysis based on nationwide cancer registry data. Cancer 1988; 62: 2274-2280.
32. Walker M. Role of hormones and growth factors in melanomas. Semin Oncol 1988; 15: 512-523.
33. Rumke O, Persijn JP, Korsten CB. Oestrogen and androgen receptors in melanoma. Br J Cancer 1980; 41: 652-655.
34. Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327: 516-523.
35. Shafie SM, Liotta LA. Formation of metastases by human breast cancer cells (MCF-7) in nude mice. Cancer Lett 1980; 11: 81-87.
36. Puistola U, Westerlund A, Kauppila A, Turpeenniemi-Hujanen T. Regulation of 72 kD type IV collagenase-matrix metalloproteinase-2 by estradiol and gonadotropin-release hormone agonist in human granulosa lutein cells. Fertil Steril 1995; 64: 81-87.